SCHEMBL20855233

SCHEMBL20855233

Cc1c(F)cc2[nH]ccc2c1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 2/20 0.42
▸ AHR P35869 5/20 0.37
▸ RHEB Q15382 1/20 0.36
▸ TRPA1 O75762 2/20 0.34
▸ CYP2A6 P11509 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ DRD1 P21728 2/20 0.32
▸ DYRK1A Q13627 2/20 0.32
▸ AURKA O14965 1/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ PRKD3 O94806 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ NTRK1 P04629 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ RET P07949 1/20 0.32
▸ IGF1R P08069 1/20 0.32
▸ MET P08581 1/20 0.32
▸ PIM1 P11309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19948493 0.81 AHR (0.39) AHRRHEBCYP2A6NR4A2DYRK1A
SCHEMBL27260931 0.78 GPR84 (0.42) GPR84AHRTRPA1DRD1DYRK1A
SCHEMBL29345927 0.78 CSNK2A1 (0.46) AHRRHEBCYP2A6NR4A2ALDH1A1
SCHEMBL10179726 0.77 GPR84 (0.45) GPR84AHRRHEBTRPA1CYP2A6
SCHEMBL10291045 0.73 AHR (0.39) AHRRHEBCYP2A6NR4A2DYRK1A
SCHEMBL13065414 0.72 AHR (0.47) GPR84AHRRHEBTRPA1CYP2A6
SCHEMBL27260926 0.71 GPR84 (0.40) GPR84AHRTRPA1DRD1DYRK1A
SCHEMBL1021334 0.71 AHR (0.45) GPR84AHRRHEBTRPA1CYP2A6
SCHEMBL29507054 0.71 AHR (0.45) GPR84AHRRHEBTRPA1CYP2A6
SCHEMBL15895157 0.71 GPR84 (0.42) GPR84AHRTRPA1DRD1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111315727-B Benzothiazole compounds and methods of treating neurodegenerative diseases using the same 第一生物治疗股份有限公司 2023-09-29 — — CN disclosed
EP-3692023-B1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST BIOTHERAPEUTICS INC (KR) 2023-05-17 — — EP disclosed
EP-3692023-B1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST BIOTHERAPEUTICS INC (KR) 2023-05-17 — — EP disclosed
US-10968188-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2021-04-06 — — US disclosed
US-20200270222-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2020-08-27 — — US disclosed
EP-3692023-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1st Biotherapeutics, Inc. (KR) 2020-08-12 — — EP disclosed
CN-111315727-A Benzothiazole compounds and methods of using the same for treating neurodegenerative diseases 第一生物治疗股份有限公司 2020-06-19 — — CN disclosed
US-10669246-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2020-06-02 — — US disclosed
WO-2019070093-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2019-04-11 — — WO disclosed
WO-2019070093-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. (KR) 2019-04-11 — — WO disclosed
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2019-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190100500-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS ABL2, ABL1, MAPT GPR84 4387/4885AHR 2885/4885RHEB 666/4885
US-10669246-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders ABL2, ABL1, MAPT GPR84 4387/4885AHR 2885/4885RHEB 666/4885
US-10968188-B2 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders ABL2, ABL1, MAPT GPR84 4387/4885AHR 2885/4885RHEB 666/4885
US-20200270222-A1 BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS ABL2, ABL1, MAPT GPR84 4387/4885AHR 2885/4885RHEB 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback